Physician profile
Robert J Olson
NPI 1356320279
$1,067.20
in general payments reported to CMS, 2019-2025
22 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $27.90 · 2021: $65.72 · 2022: $200 · 2023: $111 · 2024: $310 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $160.93 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $101.32 | 2021-2025 | Austedo Xr |
| Neuronetics, INC. | $93.92 | 2024-2025 | Neurostar Tms Therapy System |
| Harmony Biosciences LLC | $88.39 | 2024-2025 | |
| Corium, LLC | $82.20 | 2023-2024 | Azstarys, Adlarity |
| Alkermes, INC. | $66.71 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $63.72 | 2019-2025 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $59.51 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $50.56 | 2024-2025 | Fanapt |
| Indivior INC. | $38.57 | 2024-2025 | Sublocade |
| Allergan, INC. | $31.50 | 2019 | |
| Tris Pharma INC | $30.73 | 2019-2020 | |
| Abbvie INC. | $30.05 | 2022-2025 | |
| Eisai INC. | $29.79 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $27.40 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $25.53 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.97 | 2022 | |
| Soleno Therapeutics, INC. | $15.37 | 2025 | Vykat Xr |
| Novo Nordisk INC | $15.26 | 2023 | |
| Almatica Pharma LLC | $14.82 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.64 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.